34626-10-3 Usage
Imidazole family
Member It belongs to the imidazole family of compounds, which are characterized by a five-membered ring containing two nitrogen atoms.
Classification
Imidazole derivative It is a modified version of the parent compound, imidazole, with additional functional groups or substitutions.
Physical appearance
White to light yellow solid The compound has a solid form with a pale color ranging from white to light yellow.
Pharmaceutical industry use
Building block for drug synthesis It is primarily used as an intermediate compound in the synthesis of various drugs and pharmaceutical compounds.
Potential biological activities
Antimicrobial and antifungal properties It has been studied for its possible effects against microorganisms and fungi, which could lead to the development of new treatments.
Chemical reactivity
Versatile in organic synthesis As a carbonitrile derivative, it can participate in a variety of chemical reactions, making it a valuable component in organic synthesis processes.
Check Digit Verification of cas no
The CAS Registry Mumber 34626-10-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,4,6,2 and 6 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 34626-10:
(7*3)+(6*4)+(5*6)+(4*2)+(3*6)+(2*1)+(1*0)=103
103 % 10 = 3
So 34626-10-3 is a valid CAS Registry Number.
34626-10-3Relevant articles and documents
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120
Curreli, Francesca,Kwon, Young Do,Belov, Dmitry S.,Ramesh, Ranjith R.,Kurkin, Alexander V.,Altieri, Andrea,Kwong, Peter D.,Debnath, Asim K.
, p. 3124 - 3153 (2017)
In our attempt to optimize the lead HIV-1 entry antagonist, NBD-11021, we present in this study the rational design and synthesis of 60 new analogues and determination of their antiviral activity in a single-cycle and a multicycle infection assay to derive a comprehensive structure-activity relationship (SAR). Two of these compounds, NBD-14088 and NBD-14107, showed significant improvement in antiviral activity compared to the lead entry antagonist in a single-cycle assay against a large panel of Env-pseudotyped viruses. The X-ray structure of a similar compound, NBD-14010, confirmed the binding mode of the newly designed compounds. The in vitro ADMET profiles of these compounds are comparable to that of the most potent attachment inhibitor BMS-626529, a prodrug of which is currently undergoing phase III clinical trials. The systematic study presented here is expected to pave the way for improving the potency, toxicity, and ADMET profile of this series of compounds with the potential to be moved to the early preclinical development.
